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DNA hypermethylation is extensively explored as thera-
peutic target for gene expression modulation in cancer. 
Here, we re-activated hypermethylated candidate tumor 
suppressor genes (TSGs) (C13ORF18, CCNA1, TFPI2, and 
Maspin) by TET2-induced demethylation in cervical can-
cer cell lines. To redirect TET2 to hypermethylated TSGs, 
we engineered zinc ﬁnger proteins (ZFPs), which were 
ﬁrst fused to the transcriptional activator VP64 to validate 
effective gene re-expression and conﬁrm TSG function. 
ChIP-Seq not only revealed enriched binding of ZFPs to 
their intended sequence, but also considerable off-target 
binding, especially at promoter regions. Nevertheless, 
results obtained by targeted re-expression using ZFP-
VP64 constructs were in line with cDNA overexpression; 
both revealed strong growth inhibition for C13ORF18 and 
TFPI2, but not for CCNA1 and Maspin. To explore effec-
tivity of locus-targeted demethylation, ZFP–TET2 fusions 
were constructed which efﬁciently demethylated genes 
with subsequent gene re-activation. Moreover, targeting 
TET2 to TFPI2 and C13ORF18, but not CCNA1, signiﬁcantly 
decreased cell growth, viability, and colony formation in 
cervical cancer cells compared to a catalytically inactive 
mutant of TET2. These data underline that effective re-acti-
vation of hypermethylated genes can be achieved through 
targeted DNA demethylation by TET2, which can assist in 
realizing sustained re-expression of genes of interest.
Received 16 October 2015; accepted 11 December 2015; advance online 
publication 26 January 2016. doi:10.1038/mt.2015.226
INTRODUCTION
Besides genetic mutations, epigenetic silencing of tumor suppres-
sor genes (TSGs) is another important event by which normal cells 
can transform to cancer cells.1 Especially, the CpG hypermethyl-
ation observed in core promoter regions is well associated with 
gene silencing2 and is the target of a variety of therapeutic inter-
ventions aimed to restore TSG expression in cancer. In this regard, 
genome-wide epigenetic drugs, such as 5-Aza-2′-deoxycytidine 
(5-aza-dC), have been FDA approved for hematological cancers, 
but their toxicity and lack of specificity seem to limit their efficacy 
for solid tumors.3 However, developments in the field of gene edit-
ing offer a promising new approach to correct CpG methylation in 
a targeted fashion by epigenetic/epigenome editing (gene-targeted 
epigenetic reprogramming).4,5 Indeed, methylcytosine dioxygen-
ases, ten-eleven translocation (TET) proteins, have been targeted 
to sequences within hypermethylated promoter regions resulting 
in successful removal of CpG methylation at the site.6–9
For a long time, targeted DNA demethylation seemed unfea-
sible in mammalian cells as no enzymes were identified with the 
capacity to actively demethylate DNA. A breakthrough in the field 
was the identification of the TET proteins as important players in 
the active DNA demethylation pathway,10 as they catalyze the oxi-
dation of methylated CpGs (5mC) to 5-hydroxymethylcytosine 
(5hmC) and other oxidized 5mC derivatives. These intermediates 
recruit a variety of DNA repair proteins/glycosylases, such as thy-
mine-DNA glycosylase11,12 to trigger the final step of active DNA 
demethylation by the base excision repair system. The oxidizing 
properties of TET proteins make them powerful biological tools 
to demethylate DNA strands in vitro11 and in vivo.13 Gene-targeted 
demethylation initiated by TET-enzymes has attracted attention 
as an innovative approach to re-express silenced TSGs, and may 
provide new avenues to battle cancer.
Interestingly, increasing evidence is revealing that silencing 
of the TET-enzymes themselves is an important factor respon-
sible for TSG silencing14 and re-introduction of TET enzymes 
can re-activate hypermethylated TSGs.15,16 To re-activate a chosen 
TSG by targeted demethylation, TET enzymes have been linked 
to a variety of DNA targeting tools, such as zinc finger proteins 
(ZFPs)6,9 and transcription activator-like effector proteins.7,8 
Previously, the fusion of ZFPs to various effector domains (such as 
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the strong transcriptional activator VP64, generating an artificial 
transcription factor (ATF)), has proven to be an effective tool for 
modulation of gene expression in many disease models and clini-
cal trials have been performed with ZFP fusions, indicating their 
therapeutic potential.17
Epigenetically silenced TSGs in cancer are attractive targets for 
therapeutic interventions aiming to decrease DNA methylation, as 
re-activation of these, as opposed to genetically mutated TSGs, will 
result in functional proteins. In this study, we focused on four can-
didate TSGs in cervical cancer (C13ORF18, CCNA1, TFPI2, and 
Maspin), which all have been reported to be methylated/silenced in 
this malignancy.1,18–21 Of these, Maspin (SERPIN5B) has been well 
studied in cancer, but despite this, its role remains controversial.22 
TFPI2 is identified in an increasing number of cancers as DNA 
methylation marker18,23 with potent tumor suppressive activities,24 
but its function as TSG in cervical cancer is unknown. C13ORF18 
was previously identified by us as DNA methylation marker18,19 
with putative tumor suppressive activities25 in cervical cancer. 
CCNA1 is specifically methylated in various cancers.18,26
Here, we aim to validate the putative TSG function of these 
methylated genes in order to select suitable targets for targeted 
re-expression by TET2-induced DNA demethylation. First, we 
studied the epigenetic regulation of these genes in cervical cancer 
cell lines and induced effective ZFP-VP64-based gene regulation. 
Next, we showed that targeting TET2 could induce DNA demeth-
ylation and gene re-activation that translated to decreased cancer 
growth and induction of apoptosis.
RESULTS
Epigenetic Regulation of Target Genes
First, we confirmed epigenetic dysregulation of CCNA1, TFPI2, 
C13ORF18, and Maspin in a panel of cervical cancer cell lines. 
Examination of the mRNA expression revealed that CCNA1, 
TFPI2, and C13ORF18 were silenced or expressed at very low 
levels in at least 5/8 cell lines. Interestingly, Maspin was highly 
expressed in 7/8 cell lines (Figure 1a). This unexpected finding 
was also found on protein level in a panel of cervical cancer cell 
lines, and could be confirmed for cervical cancer patient samples 
(Supplementary Figure S1); we found high Maspin expression in 
tumor cells as opposed to the normal adjacent cells, while Maspin 
methylation levels in cervical cancer patients were decreased. In 
the cell lines, we also confirmed that Maspin was not mutated, 
indicating that Maspin is functionally active. For HeLa, SiHa, and 
Caski, the expression of Maspin was associated with the presence 
of active histone marks (H3K4Me3 and H3K9Ac) and the absence 
of repressive marks (H3K9Me3 and H3K27Me3). The silencing of 
CCNA1 and C13ORF18, and to a lesser extend TFPI2, was associ-
ated with the presence of H3K9Me3 in these cell lines (Figure 1b). 
In addition to the histone marks, DNA methylation was closely 
correlated with the gene expression status (Figure 1c), without a 
clear association with cellular TET expression (Supplementary 
Figure S2).
All silenced genes could be re-expressed by epigenetic drugs, 
with induction levels reaching up to ~2700-fold and ~6900-fold 
for CCNA1 and TFPI2, respectively, and 20-fold for Maspin 
(Figure 1d–f). Compared to C13ORF18 (±50-fold),25 CCNA1 and 
TFPI2 were much more responsive to epigenetic drug treatment. 
Methylation-specific PCRs proved that upregulations were at least 
partly the result of promoter demethylation (Supplementary 
Figure S1). Together, these results confirmed that CCNA1, TFPI2, 
and C13ORF18 were epigenetically repressed in cervical cancer, 
but Maspin seemed to be overexpressed.
Target Validation by ZFPs Fused to VP64
To achieve ZFP-mediated gene targeting for CCNA1 and TFPI2, we 
engineered in total 17 ZFPs (Figure 2a). ZFPs were subsequently 
fused to VP64 and screened for their ability to modulate endog-
enous expression of CCNA1 (6 ZFPs) or TFPI2 (11 ZFPs). From 
the six ATFs targeted to the CCNA1 promoter, an initial screen-
ing in HeLa revealed 12ab-VP64 as a robust inducer of CCNA1 
expression (Supplementary Figure S3a). Further validation of 
12ab-VP64 in the CCNA1 repressed cell lines SiHa, CaSki, and 
C33A revealed that 12ab-VP64 consistently induced expression 
of CCNA1 mRNA up to 66-fold (Supplementary Figure S3a). 
From the 11 ATFs targeted at the TFPI2 promoter, 43ab-VP64 
was the most robust re-activator of TFPI2 in methylated HeLa and 
SiHa cells, with induction levels up to 23-fold (Supplementary 
Figure S3b). We also confirmed induction of Maspin expression 
by published Maspin-targeting ATFs (126-VP64 and 97-VP64)27 
in the cervical cancer cell lines CaSki and C33A (Supplementary 
Figure S3c). Previously, we showed induction of C13ORF18 in 
these cervical cancer cell lines.25
We further validated the selected VP64-ATFs in four low pas-
sage cervical cancer cell lines.28 Two of these cell lines grow as 
spheres (CSCC-7 and CC-11), better representing primary tumor 
characteristics (Supplementary Figure S4a). For comparison, 
CC-11 cells were also transduced with viruses to directly express 
the target cDNA (Figure 2b–e, right bars). The ATFs consistently 
upregulated their target genes C13ORF18, CCNA1 or TFPI2 in 
all cell lines (Figure 2b–e) with no/very low cross-inductions of 
these other genes (Supplementary Figure S4b–g). Maspin was 
highly expressed in all four cell lines, and ATFs could not further 
upregulate Maspin in these cells.
Binding Proﬁles of Engineered ZFPs
In order to gain greater insight into the specificity of our ZFPs, 
ZFP-binding profiles were determined by ChIP-Seq. ZFPs with-
out effector domain were used, as it was observed that effector 
domains, such as VP64, can shield the HA tag from detection by 
our antibody. PCR on the sonicated fragments revealed a close 
association of the ZFPs with their targeted promoter (Figure 3a).
Subsequently, these samples were subjected to genome-wide 
sequencing and again we demonstrated binding of the ZFPs to their 
intended promoters (Figure 3b and Supplementary Figure S5). 
For example, 3ab-targeting C13ORF18 showed substantial enrich-
ment at the methylated C13ORF18 promoter. However, also off-
targets were detected (Supplementary Figure S6 and S7). While 
the empty vector revealed a relatively steady background signal 
throughout the genome (Supplementary Figure S6a) (many 
peaks, but with low coverage (Figure 3c), ZFPs seemed to have 
site preferences (Supplementary Figure S6a). Interestingly, for all 
analyzed ZFPs targeting closed chromatin (3ab, 5ab, and 12ab), 
off-target binding events within our four target loci were most 
pronounced in the promoter region of active (TFPI2, Maspin in 
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Figure 1 Epigenetic regulation of putative tumor suppressor genes in a panel of cervical cancer cell lines. (a) mRNA expression relative to 
GAPDH of CCNA1, TFPI2, C13ORF18 and Maspin in a panel of eight cervical cancer cell lines. (b) Quantitative ChIP for repressive histone marks 
(H3K9me3 and H3K27me3) and histone marks associated with active gene-transcription (H3K4me3, H3K9Ac, H3Ac, and H4Ac) for the gene promot-
ers of CCNA1, TFPI2, C13ORF18 and Maspin in HeLa, SiHa, and CaSki (H3K9Ac, n = 2). (c) Methylation status of the CCNA1, TFPI2, C13ORF18 and 
Maspin promoter of CpGs in the indicated region. Methylation levels were analyzed by bisulﬁte sequencing (each circle represents the average of 
three or more clones) or bisulﬁte pyrosequencing (average methylation of cell population). Re-expression/upregulation of CCNA1 (d), TFPI2 (e), and 
Maspin (f) mRNA after treatment with different concentrations of epigenetic drugs (500 nM (+), 5 μM 5-aza-dC (++) and/or 500 nM TSA (+)). Values 
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CaSki cells) and not repressed loci (C13ORF18, CCNA1 in CaSki 
cells). Strikingly, such off-target effects can be very pronounced 
especially for DNA segments with a high sequence similarity 
with the 18-bp target region. As an example, we analyzed bind-
ing sites for the 12ab ZFP and found significant enrichment for 
DNA segments with a single mismatch within the ZFP target site 
(Supplementary Figure S6b and S7). Such off-targets by sequence 
similarity can result in peaks with high coverage, even for 2 bp 
mismatches, as shown for 12ab-NoEf off-targets with mismatches 
at the edges of the target site (Supplementary Figure S7).
Then, for each ZFP the total number of off-targets was deter-
mined (with a coverage of five or more). We found many peaks 
Figure 2 Re-expression of candidate TSGs (C13ORF18, CCNA1, TFPI2 and Maspin) in tumor-derived cell lines. (a) Schematic representations 
of 18-bp ZFPs (not on scale) binding to DNA. Also shown are the promoter region of CCNA1, TFPI2, Maspin and C13ORF18 stretching from −750 
to +750 bp relative to the main TSS of the corresponding genes. Indicated are the targeted sites of the ZFPs directed to the CCNA1, TFPI2, Maspin 
and C13ORF18 promoter, as well as ZFPs which successfully demonstrated gene expression modulation when fused to effector domains. CpGs are 
indicated as vertical bars. Gene expression levels of C13ORF18 (b), CCNA1 (c), TFPI2 (d) and Maspin (e) mRNA relative to empty vector after retroviral 
transduction with gene-targeting ATFs (C13ORF18: 3ab-VP64, 5ab-VP64; CCNA1: 12ab-VP64; TFPI2: 43ab-VP64; and Maspin: 126-VP64) in CSCC-7, 
CSCC-8, CC-10 and CC-11. CC-11 cells were also transduced with cDNA overexpression constructs of C13ORF18, CCNA1, TFPI2 and Maspin. Each 
bar represents the mean of in general three independent measured in triplicate ± SEM. Quantiﬁcation of mRNA was performed using qRT-PCR and 
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for the ZFPs (Figure 3c), although also empty vector had many 
peaks, albeit mostly with low coverage. Compared to empty vec-
tor, ZFP binding was enriched at promoter regions, but not at dis-
tal promoter segments and gene bodies, as shown for peaks with 
ten or more reads (Figure 3d). The total number of mistargeted 
promoters was several-fold higher compared to an empty vector 
(between 806 and 5984 for the various constructs, empty vector 
204) (Figure 3e). The TFPI2-ZFP showed the least off-targets, 
although a difference in viral load between the different ZFP con-
structs may have influenced the number of mistargeted promoters.
Re-expression of Silenced TSGs Results in Suppressive 
Effects in Tumor-derived Cell Lines
To determine which genes within our panel of hypermethylated 
genes have a tumor suppressive function, we re-activated gene 
expression using the VP64-ATFs. In HeLa cells, TFPI2-induced 
Figure 3 Genome association of ZFPs. (a) ATF association of C13ORF18-, CCNA1-, and TFPI2-targeting ZFPs with their respective gene promot-
ers (C13ORF18: empty vector, 3ab-NoEf and 5ab-NoEf; CCNA1: 12ab-NoEf; and TFPI2: 43ab-NoEf) as detected by ChIP using an anti-HA antibody. 
(b) Coverage plots showing the local enrichment for binding of 43ab-NoEf at the targeted TFPI2 promoter in a 20-kb spanning region visualized with 
RStudio (cells expressing an empty vector were used as control). Local enrichment was determined using the coverage distribution report obtained 
from NextGENe. See Supplementary Figure S5 for binding of 3ab-, 5ab-, 12ab-, and 43ab-NoEf to all promoters (C13ORF18, CCNA1, TFPI2, and 
Maspin). (c) Representation of the identiﬁed ChIP-Seq peaks with coverage of ﬁve or more for the gene-targeting constructs and an empty vector 
as determined by the peak identiﬁcation report obtained from NextGENe. (d) Percentage of ChIP-Seq peaks (with coverage of ten or more reads) 
bound to promoters, distal promoters and gene bodies (thus the region −10,000 until +10,000 bp relative to the TSS with the exception of the region 
+/− 100 bp relative to the TSS) or other regions (such as non-coding DNA). (e) Graphical representation of the number of peaks and their coverage 
at the mistargeted promoters from d.
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expression by 43ab-VP64 significantly decreased cell viability 
(−85% (P < 0.01)) 4 days after transduction compared to empty 
vector (Figure 4a), but this effect was not seen for 12ab-VP64 
targeting CCNA1. In CC-11 cells, all silenced genes could be 
upregulated by our ATFs (Figure 2), and therefore this cell line 
was chosen to compare the differences in the effect on cell growth 
between these genes (Figure 4b). We found that C13ORF18- and 
TFPI2-inducing constructs significantly reduced cell growth com-
pared to empty vector (3ab-VP64 −45% (P < 0.05), 43ab-VP64 
−58% (P < 0.01)), while CCNA1-inducing constructs had no effect 
on cell growth. As controls, we expressed cDNA constructs of the 
four genes in CC-11 cells and measured the percentage of late 
apoptotic/necrotic cells (Figure 4c). We found again indications 
that TFPI2 and C13ORF18 are TSGs; both C13ORF18 and TFPI2 
cDNA overexpression significantly induced cell death compared 
to an empty vector, while the cell death induced by CCNA1 or 
Maspin overexpression did not reach significance. In all assays, 
TFPI2 was identified as the strongest growth inhibitor.
Epigenetic Editing by TET2
In contrast to transcriptional activators, such as VP64, (a com-
bination of) epigenetic editing approaches could provide us with 
the tools to ultimately re-express silenced TSGs in a sustained 
fashion.9 Therefore, to assist in realizing this goal, we fused TET2 
and its catalytically inactive mutant to our selected panel of ZFPs 
targeting silenced genes. TET2 was selected based on our previ-
ous observations that TET2 was the most efficient DNA demeth-
ylating enzyme when targeted to the ICAM-1 promoter.6 To reach 
optimal/more effective levels of ZFP–TET2 constructs, cells were 
GFP sorted and re-transduced before analysis (superinfection) 
(Figure 5a and Supplementary Figure S8a,b); this procedure 
increased transgene expression to ~10-fold. Similarly, superin-
fection compared to regular infections of VP64-ATFs resulted in 
higher gene inductions for all four genes (Supplementary Figure 
S8c–e). Subsequently, we showed that the promoter of C13ORF18 
could be significantly re-activated by TET2-mediated gene target-
ing in CaSki cells, whereas the TET2 mutant did not significantly 
affect gene expression (Figure 5a). Re-expression of C13ORF18 
by 5ab fused to the catalytic domain of TET2 (5ab-TET2-CD) 
reached induction levels up to 59-fold (P < 0.01) (Figure 5a) rela-
tive to empty vector. Expression of GFP (as surrogate marker for 
construct expression) showed only minor differences between 
TET2 and its mutant (Supplementary Figure S8a). To determine 
whether the C13ORF18 induction by TET2 was associated with 
DNA demethylation at the promoter region, an initial screening 
was performed using bisulfite sequencing upon expression of 
ATFs and TET2 fusions on regularly infected cells. This screen 
revealed that the promoter region of C13ORF18 was partially 
demethylated by the TET fusions, especially around the 5ab-bind-
ing site (Supplementary Figure S9a,b). To quantify the reduc-
tion in methylation levels on single CpGs, we performed bisulfite 
pyrosequencing for six CpGs surrounding the 5ab-target site on 
superinfected cells (Figure 5b,c). We observed effective DNA 
demethylation of the CpGs by the TET2 constructs both at the 
three CpGs at the 5′ flanking side of the ZFP-binding site (reduc-
tion of 48% (P < 0.001), 50% (P < 0.001) and 44% (P < 0.001)) as 
well as at the 3′ flanking side of the ZFP-binding site (reduction 
of 19% (P < 0.01), 37% (P < 0.01) and 11% (P < 0.09)). Also the 
simultaneous expression of 3ab+5ab-TET2-CD resulted in sig-
nificant demethylation of the targeted CpGs, although to a lesser 
extent (up to 21% (P < 0.001), Figure 5c). The control constructs 
(empty vector, VP64-ATF, and NoEf) did not induce significant 
demethylation of the analyzed CpGs around the 5ab target site.
Then, we determined robustness of the approach by target-
ing TET2 to the CCNA1, TFPI2, and Maspin promoters. When 
fused to 12ab, TET2, but not the mutant, induced upregulation 
of CCNA1 up to ~58-fold (P < 0.01) (Figure 5d), which was 
Figure 4 Tumor suppressive effects of candidate TSGs. (a) Cell 
 viability of HeLa cells after re-expression of silenced CCNA1 and TFPI2 
by 12ab-VP64 and 43ab-VP64, respectively. (b) Cell viability of CC-11 
cells after gene induction/upregulation of C13ORF18, CCNA1, TFPI2, and 
Maspin by 3ab-VP64, 12ab-VP64, 43ab-VP64, and 126-VP64, respec-
tively. Cell proliferation was assessed using a MTS assay during 5 days 
and empty vector and ZFP-NoEf were used as controls. (c) Percentage 
of cell death after treatment with empty vector, C13ORF18-, CCNA1-, 
TFPI2-, and Maspin-cDNA overexpression constructs in CC-11 cells. Each 
data point represents the mean of three or more independent experi-
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associated with demethylation of several CpGs in the vicinity of 
the 12ab target site and in the direction of the TET-enzyme (10 
CpGs analyzed) (Figure 5d); CpGs were demethylated up to 43% 
compared to controls. Re-expression of TFPI2 by 43ab-TET2-CD 
reached induction levels up to ~7-fold (P < 0.05) (Figure 5e), 
while the targeting of TET2 in Maspin-methylated C33A cells did 
not result in significant activation of Maspin (data not shown). 
For the 5-aza-dC-treated cells (Figure 1d), only a limited effect 
on DNA methylation was observed for most of the analyzed CpGs 
(Figure 5c,d).
To gain a first insight into whether targeted TET2-constructs 
only affect methylation of ZFP-bound regions (as determined 
by ChIP-seq), we investigated the effect of the targeted TET2-
constructs on the methylation level of a small selection of non-ZFP 
bound promoters. Based on the ChIP-Seq analysis, the C13ORF18 
targeting ZFP did not bind the CCNA1 promoter and the CCNA1-
ZFP did not bind to the C13ORF18 promoter (Supplementary 
Figure S5). Therefore, these regions were selected for analysis. 
Indeed, most of the CpGs remained unaffected, although within 
the C13ORF18 promoter the methylation level of one CpG was 
significantly reduced (−10%) by the 12ab-TET2-CD targeted at 
the CCNA1 promoter. Similarly, analysis of a third methylated 
promoter (EPB41L3, Supplementary Figure S10) showed sig-
nificant demethylation (−10%) of only 1 out of 30 off-target CpGs 
analyzed.
Until now, it has not been determined whether re-activation 
by targeted TET2 to hypermethylated genes can decrease tumor 
growth. To investigate the feasibility of this approach, we targeted 
TET2 to the TFPI2 promoter, as cDNA and VP64-ATFs identi-
fied TFPI2 as the strongest growth inhibitor (Figure 4). Indeed, in 
CC-11 cells transduced with TFPI2-targeting constructs, a strong 
and significant reduction in CC-11 colony size was revealed com-
pared to empty vector (Figure 6a,b); expression of 43ab-TET2 
reduced colony size with 68% (P < 0.01). Moreover, targeting TET2 
to TFPI2 and C13ORF18, but not CCNA1, decreased cell prolifera-
tion of HeLa and Caski cells compared to a catalytically inactive 
mutant of TET2 (Figure 6c,d), and this was accompanied with an 
increase in the fraction of late apoptotic/necrotic cells (Figure 6e,f). 
These data underline that effective re-activation of hypermethyl-
ated genes can be achieved through targeted DNA demethylation.
DISCUSSION
Potentially new approaches for cancer treatment are appearing 
using the TET-methylcytosine dioxygenases as a tool to directly 
mediate CpG demethylation and restore gene expression.6,7,15,16 In 
this study, we showed that by targeting TET2 to hypermethylated 
TSGs, efficient DNA demethylation can be achieved, resulting in 
significant gene re-activation. We found that the induced demeth-
ylation by ZFP–TET2 fusions can result in significantly less tumor 
growth. Analysis of TET1-3 expression revealed that TET1 was 
significantly silenced in cervical cancer, while TET2 was highly 
expressed compared to normal cells, without a clear association 
with TSG hypermethylation. The most promising therapeutic 
target we identified from the four putative TSGs (C13ORF18, 
CCNA1, TFPI2, and Maspin) was TFPI2, and this is the first study 
describing its role in this malignancy. Moreover, we demonstrate 
the binding of the engineered ZFPs to their aimed methylated tar-
get site, and off-target DNA demethylation events were rather lim-
ited within our panel of genes. However, the ChIP-Seq revealed 
that the ZFPs exhibit off-target binding, especially to promoter 
areas (several fold more enrichment of the ZFPs at other gene 
promoters compared to a control). In addition, we found that the 
well-described TSG Maspin was unexpectedly highly expressed in 
cervical cancer.
Previously, the targeting of TET1 resulted in substantial DNA 
demethylation and upregulation of the targeted HOXF2- and beta-
globin genes.7 Moreover, targeted demethylation by TET1 of the 
metastasis suppressor gene CRMP4 abolished metastasis in pros-
tate cancer cells.8 Here, we showed that also the targeting of TET2 
to hypermethylated genes results in substantial CpG demeth-
ylation and gene re-expression, which was effective enough to 
translate to reduced cancer cell growth. Demethylation of single 
CpGs was observed with reductions up to 50% for C13ORF18 and 
59% for CCNA1, resulting in significant gene inductions (up to 
~59- and ~58-fold, respectively). Compared to our initial report, 
in which we screened for efficiency of ZFP-targeted TET1, TET2, 
and TET3, this study describes a more effective DNA demethyl-
ation and higher gene induction for TET2 (2-fold induction and 
~6% demethylation for targeting the ICAM-1 promoter).6 The 
improved efficiency may be explained using the superinfection 
procedure, as we observed more demethylation of target CpGs 
after re-infecting the cells, thereby increasing the expression of and 
exposure time to the TET fusions. Also, the addition of epigenetic 
drugs has shown to facilitate re-expression by DNA demethylat-
ing reagents, possibly through inhibition of DNMT3B.9
TET2-induced DNA demethylation was very pronounced at 
both sides of the binding site (within 50 bp), although the bisul-
fite sequencing data for C13ORF18 indicates a more widespread 
Figure 5 TET2-mediated gene activation and demethylation. (a) Relative C13ORF18 mRNA expression (left) after retrovirally induced expression of 
ZFPs carrying GFP and either TET2-CD, TET2-mutant or NoEf. On the right, the GFP positivity of transduced cells as exempliﬁed for untreated cells or 
cells expressing an empty vector, 5ab-VP64 or 5ab-TET2 measured by FACS. (b) Schematic representation of the C13ORF18 promoter region carrying 
the target site of 5ab-TET2-CD and six CpGs surrounding this site. (c) The DNA methylation status of the six CpGs in the C13ORF18 promoter after 
expressing the gene-targeting constructs or treatment with 5-aza-dC (5 μM for 3 days (n = 3 samples from Figure 1d–f)) as quantiﬁed by bisulﬁte 
pyrosequencing. Values represent the mean of at least two independent experiments ± SEM. (d) Relative CCNA1 expression after retrovirally induced 
expression of ZFPs carrying either TET2-CD, TET2-mutant or NoEf in CaSki cells (left). On the right, the DNA methylation status of 10 CpGs in the 
CCNA1 promoter after expressing the gene-targeting constructs 12ab-TET2-CD and 12ab-VP64 (or treatment with 5-aza-dC (5 μM for 3 days (n = 3)) 
as quantiﬁed by bisulﬁte pyrosequencing. Statistical differences were determined between empty vector and 12ab-TET2-CD. (e) Relative TFPI2 mRNA 
expression after retrovirally induced expression of ZFPs carrying either TET2-CD or NoEf in HeLa cells. All cells were GFP sorted (except NoEf) after 
transduction and re-transduced before analysis. Expression of C13ORF18, CCNA1, and TFPI2 is normalized to GAPDH and relative to an empty vector. 
mRNA was quantiﬁed by qPCR and each bar represents the mean of at least three independent experiments measured in triplicate ± SEM. (f) The 
off-target effect of the C13ORF18-targeting 5ab-TET2 ZFP and the NoEf control on the methylation status of the CCNA1 promoter. (g) The off-target 
effect of the CCNA1-targeting 12ab-TET2 ZFP and the NoEf control on the methylation status of the C13ORF18 promoter. Methylation levels were 
quantiﬁed by bisulﬁte pyrosequencing and each data point represents the mean of three independent experiments ± SEM
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effect. These results are in line with the DNA demethylating effects 
of TET1, which were greatest within 30 bp of either end of the 
transcription activator-like effector target-binding site, but could 
reach up to 150–200 bp away of the target site.7 The observed CpG 
demethylation after targeting TET enzymes could even be an 
underestimation, as TET enzymes will first convert 5mC to 5hmC, 
and this modification cannot be differentiated from methylated 
Cs by bisulfite pyrosequencing. In addition, the targeting of TDG 
has shown to mediate expressional changes by reducing methyla-
tion levels, although to a smaller extend.29 Such rewriting of the 
methylation code by enzymes that initiate CpG demethylation 
is of key importance to achieve sustained re-expression of target 
genes; Indeed, Li et al.8 demonstrated that TET1-induced DNA 
demethylation of the tumor metastasis suppressor gene CRMP4 
resulted in a reduction of metastasis formation up to 60 days after 
induction of targeted DNA demethylation. VP64-ATF-mediated 
expressional changes have shown to be only transient, as tar-
geted promoters are incompletely reprogrammed and genes tend 
to return to the ‘normal’ state after the VP64-ATF is removed.9 
Previously, it was observed that VP64-induced gene activation of 
ICAM-1 results in DNA demethylation.6 However, this response 
seems dependent on the local chromatin environment, as here, 
we did not observe such an effect on DNA demethylation induced 
by VP64 for either C13ORF18 or CCNA1. This finding highlights 
the importance to look into the local chromatin environment to 
achieve a sustainable response.
Interestingly, 5-aza-dC induced high gene expression levels 
of our target genes, but this was not associated with much DNA 
demethylation within the analyzed regions, as demonstrated 
by bisulfite pyrosequencing of the C13ORF18 and CCNA1-
promoter. The last decade, treatment with DNA demethylating 
agents has been used extensively to demonstrate epigenetic reg-
ulation of silenced genes, but indirect 5-aza-dC effects are com-
monly observed.30 Indeed, lack of gene DNA demethylation after 
5- aza-dC-induced expression has been reported many times in lit-
erature, for example, for Maspin31, and may also partly explain the 
commonly observed lack of sustainability on gene expression after 
such treatment.30 The epigenetic editing approach described here 
to demethylate genes is believed to be a more specific approach 
compared to 5-aza-dC. Despite this, as shown by the ChIP-Seq 
analysis, also the epigenetic editing approach still requires further 
optimization to make it more specific.
With the development of the transcription activator-like 
effectors and the recent clustered regularly interspaced short 
palindromic repeat (CRISPR)/Cas9 system, gene targeting for 
(epi)genome editing purposes has made a real boost.32 The 
advantage of ZFPs is their small size, making them efficient 
in accessing epigenetically silenced regions. With regard to 
Figure 6 TET2-mediated reduction of cell growth by targeting TFPI2. (a) Visualization of CC-11 colonies after expressing the TFPI2-targeting ZFPs 
(43ab) carrying TET2 and controls constructs (empty vector, 43ab-VP64, and TFPI2-cDNA). Pictures are a representative of two independent experi-
ments. (b) Quantiﬁcation of the colony size of CC-11 cells from a using ImageJ. Each bar represents the average colony size per condition from two 
independent experiments. For each condition, four pictures were randomly taken. Cell viability of HeLa (c) and CaSki (d) cells 5 days after transduc-
tion with the gene-targeting constructs measured with a MTS assay. The fraction of late apoptotic and necrotic cells 5 days after transduction with 
the gene-targeting zinc ﬁngers (43ab targeting TFPI2, 5ab targeting C13ORF18, and 12ab targeting CCNA1) fused to VP64, TET2 or TET2 mutants 
measured with a PI assay in HeLa (e) and CaSki cells (f). Transductions were performed on superinfected cells and each data point represents the 
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off-target effects, some reports indicated that ZFP-ATFs can 
manipulate gene expression with single gene resolution29,33 and 
we previously found that of all protein-coding loci, the E2C-
engineered ZFP preferentially binds to its aimed target site.34 All 
three targeting systems are currently improved to yield highly 
specific genome editing tools when fused to endonucleases.35 
Here, we could demonstrate that our ZFPs bind to their endoge-
nous methylated target site using ChIP-Seq, while no binding to 
off-target methylated sites was detected for our gene panel. This 
was in line with little or no off-target DNA demethylation events 
at these methylated promoters. However, when looking at the 
genome-wide scale, we did observe that the ZFPs exhibit off-
target binding, as the ChIP-Seq revealed that several-fold more 
off-target promoters showed enrichment for the ZFPs compared 
to a control. In line with this, Grimmer et al.36 reported thou-
sands of off-target sites, mainly at promoter regions, for ZFPs 
targeted to the SOX2 promoter. Within our small panel of target 
genes, we observed preferential off-target binding to the pro-
moters of the actively transcribed genes (TFPI2 or Maspin). For 
example, ZFP 3ab targeted to C13ORF18 was also enriched at 
the Maspin promoter. On the other hand, only ZFPs targeted to 
repressed promoters (12ab to CCNA1, 3ab or 5ab to C13ORF18) 
were specifically enriched at those difficult to access regions (for 
our gene panel). High sequence similarity with intended target 
sites could further enhance off-target effects, as shown here for 
a 1–2 bp mismatch for the CCNA1-ZFP. Based on ongoing ZFP 
clinical trials, which did not result in adverse effects, we reason 
that the off-target issue can be solved/specificity of the approach 
is likely to be increased by, e.g., the targeting of multiple con-
structs to a single promoter, as well as the use of split enzyme 
approaches.37 Alternatively, other DNA binding approaches 
might provide more specific agents in the future, as is demon-
strated by ongoing CRISPR/Cas efforts.32
After the realization that TSG silencing by epigenetic mecha-
nisms is associated with carcinogenesis, enormous efforts have 
been undertaken to identify those genes for diagnostic or thera-
peutic strategies, and such studies have contributed to the discov-
ery of novel TSGs. The diagnostic value or observed gene silencing 
of our chosen panel of genes has been described in several stud-
ies,1,18,20,21,38 but so far, only a few studies have been performed to 
explore the functional consequences of silencing and the poten-
tial therapeutic effects of re-expression within this malignancy. 
In this study, we included low passage cell lines to study functional 
effects, which may be more representative for primary cervical 
tumors compared to the long established cell lines. The use of such 
cell lines may help to bridge the gap with real tumors.
For C13ORF18 and TFPI2, we found growth inhibitory effects, 
but not for CCNA1 and Maspin. To our knowledge, this is the first 
report that demonstrates that TFPI2 is a TSG in cervical cancer 
cell lines using either cDNA overexpression or ATF-induced 
 re-expression. Interestingly, Maspin seems to be less important as 
TSG in cervical cancer. We found that Maspin is unmethylated 
and highly expressed in cervical cancer, and our constructs did 
not decrease tumor growth. Although regarded as important ther-
apeutic target in cancer for a long time, the latest insights suggest 
that the role of Maspin in cancer may need revision and does not 
have a tumor suppressive function.22
In conclusion, in this study we employed three different 
approaches to re-activate dormant TSGs and that may affect DNA 
methylation levels: epigenetic drugs, VP64-ATFs, and ZFP–TET2 
constructs. In contrast to ZFP–TET2 constructs, epigenetic drugs 
and VP64-ATFs did not efficiently initiate demethylation at tar-
geted CpGs, despite resulting in more efficient gene re-activation. 
Therefore, these two latter approaches seem not to be the most 
suitable approach for sustained gene re-activation, as this requires 
changes in the local epigenetic landscape. Our TET2-mediated 
approach delineates an efficient way to demethylate targeted CpGs, 
resulting in TSG re-expression and growth inhibition, and such 
approach can be extended to other genes as well. Such approach 
may be more sustainable than re-activation by VP64 and more 
specific compared to epigenetic drugs. Furthermore, our ZFPs 
may also serve as flexible tools to screen other putative demeth-
ylases or to compare demethylating efficiencies between demeth-
ylases (e.g., TDG versus TET). We also showed that TFPI2 and 
C13ORF18 are stronger tumor suppressors compared to CCNA1 
and Maspin. For permanent re-expression of silenced genes, 
future efforts to further unravel the elusive DNA demethylation 
pathway39 may give clues to increase the efficiency of targeted 
demethylation to gain permanent control over the transcriptome.
MATERIALS AND METHODS
Cell Culturing. The human cervical cancer cell lines HeLa, SiHa, CaSki, 
C33A and the human embryonic kidney cells HEK293T were obtained 
from the ATCC (Manassas, Virginia) and authenticity of the cell lines 
was verified by DNA short tandem repeat analysis (Baseclear, Leiden, The 
Netherlands). The CSCC-7, CSCC-8, CC-10, and CC-11 were derived from 
cervical squamous cell carcinoma as described previously28 and were kindly 
provided by Prof. GJ Fleuren (Leiden University Medical Center, Leiden, 
The Netherlands). The normal healthy human control cells (conditionally 
immortalized ovarian epithelial cells (OSE-C2) and skin fibroblasts (adult 
donor)) were, respectively, kindly provided by Dr. Richard Edmondson 
(Newcastle University, UK) or obtained from ATCC (CCD-1093SK). All 
cell lines were cultured in DMEM (BioWhittaker, Walkersville, Maryland), 
supplemented with 10% fetal calf serum (BioWhittaker), 1% l-glutamine 
and 0.6% gentamycin, at 37 °C under 5% CO2. For treatment with epi-
genetic drugs, cells were treated with 500 nM or 5 μM 5-aza-dC (Sigma, 
St Louis, Missouri) for three consecutive days. 500-nM TSA (Sigma) was 
added on the third day. Cells were harvested on the fourth day for analysis.
Cloning and Delivery. Target sites of engineered ZFPs were selected based 
on ranking according to Zincfingertools.org40 and the proximity to the 
transcription start site of targeted genes (−500 bp to +250 bp) (Figure 
2a). The coding sequences of their DNA-specific binding domains are 
shown in Supplementary Table S1 and were established using the amino 
acid-DNA binding code.41 Sequences were ordered as double stranded 
DNA oligos (BIO BASIC, Markham, Canada) flanked with SfiI (Thermo 
Scientific, Leon-Rot, Germany) restriction sites at the N-terminus 
5′-GGATCCGAGGCCCAGGCGGCC-3′ and C-terminus 5′-GGCCAGG 
CCGGCCGAAGATCTGAGGAG-3′. ZFPs were subsequently subcloned 
in the pMX-IRES-GFP carrying either the transcriptional activator VP64, 
no effector domain (NoEf), TET2-CD or TET2-mutant6 using SfiI restric-
tion. For ectopic expression of C13ORF18, CCNA1, TFPI2, and Maspin 
cDNA, DNA fragments of the genes were generated by PCR (Phusion Hot 
Start II High-Fidelity DNA polymerase, Thermo Scientific) using gene-
specific PCR primers (Supplementary Table S2) flanked with BamHI and 
NotI (C13ORF18, TFPI2) or BglII and EcoRI (CCNA1, Maspin) restric-
tion sites on pre-ordered cDNA carrying plasmids (C13ORF18 isoform 
a (Invitrogen, Life Technologies, Carlsbad, California), CCNA1 isoform 
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a (Invitrogen) and TFPI2 isoform 1 precursor (BIO-BASIC)) or cDNA 
obtained from HeLa cells (Maspin) and ligated into the pMX-IRES-GFP.
Retroviral transduction was performed as previously described.25 For 
superinfection, harvested cells were GFP sorted using the MoFlo-XDP 
sorter (Beckman Coulter, Woerden, The Netherlands), re-seeded and 
propagated. Subsequently, cells were re-transduced and harvested using 
the same procedure as normal transduction, or frozen in liquid nitrogen 
for later re-transduction.
ChIP(-Seq). ChIP(-Seq) was performed as previously described9 using the 
following antibodies: normal rabbit IgG (ab46540), H3K36Me3 (ab9050) 
(Abcam, Cambridge, UK), acH3 (06-599), acH4 (06-598), H3K4Me3 (07-
473), H3K9me3 (07-442) and H3K27me3 (07-449, Millipore, Billerica, 
Massachusetts), H3K9Ac (39137, Active Motif, La Hulpe, Belgium) or 
anti-HA-tag (101P-200, Covance, Uden, The Netherlands). The cover-
age for the ChIP-Seq peaks was calculated by NextGENe by dividing the 
number of bases aligned to the region by the length of the peak. See the 
Supplementary Materials and Methods for a more extensive description.
Bisulﬁte Sequencing/Methylation-Speciﬁc PCR/Bisulﬁte Pyrosequencing. 
Methylation-specific PCR and bisulfite sequencing were performed as 
previously described25 using gene-specific primers (Supplementary Table 
S2). Bisulfite pyrosequencing was performed on the Pyromark Q24 MD 
pyrosequencer (Qiagen) according to the manufacturer’s instructions. 
Methylated levels of single CpGs were determined using Pyromark Q24 
Software (Qiagen).
Quantitative Real-time PCR (qRT-PCR). RNA was isolated using the 
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and converted into 1 
μg of cDNA (Thermo Scientific). qRT-PCR was performed as previously 
described9 using gene-specific primers (Supplementary Table S2). Gene 
expression levels relative to GAPDH were determined with the formula 
2 t−ΔC . Fold increase in gene-expression compared to controls was calcu-
lated with the formula 2 t−ΔΔC . Samples for which no amplification could 
be detected were assigned a  Ct value of 40, resembling the total number 
of PCR cycles.
Growth Assay/Propidium Iodide Assay. Cells were seeded in 96-wells 
plates (2,000 cells per well), transduced and incubated for 1 to 5 days at 
37 °C. To measure the fraction of viable cells, 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
(5 mg/ml) was added, followed by 3 hours of incubation at 37 °C. Then, 
the absorbance was detected at 490 nm with a Versamax microplate reader 
(Molecular Devices, Sunnyvale, California).
Four days after transduction, the fraction of cell death (late apoptotic 
and necrotic cells) was determined using propidium iodide as previously 
described.42 The colony size of CC-11 cells was measured 5 days after viral 
delivery using ImageJ (version 1.49m).
Statistical Analysis. Statistical significance was determined with the 
Student’s t-test (single group comparison) or one-way ANOVA (multiple 
group comparison) followed by Dunnett’s post hoc test using GraphPad 
Prism 5 software. A P-value of 0.05 or less was considered statistical sig-
nificant (*P ≤ 0.05, **P < 0.01, and ***P < 0.001).
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Figure S2. TET 1-3 expression in healthy control cells and cervical 
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Figure S3. Endogenous re-expression of CCNA1, TFPI2 and Maspin 
mRNA by ATFs.
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CC-10, and CC-11.
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Figure S6. Genome-wide binding of the various gene-targeting 
constructs.
Figure S7. Off-targets caused by sequence similarity.
Figure S8. Relative GFP mRNA expression after retroviral treatment 
with C13ORF18- and CCNA1-targeting constructs in CaSki.
Figure S9. Demethylation of the C13ORF18 promoter after ZFP-
mediated targeting of TET2 or VP64.
Figure S10. Off-target effects of TET-ZFPs on EPB41L3 promoter 
methylation
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Maspin.
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